Prosecutors announced Tuesday morning that there is potential for a superceding indictment against Martin Shkreli, including securities fraud.
The prosecutor said the new charges would be related to existing allegations that Shkreli and co-defendant Evan Greebel defrauded Retrophin and that no new individuals would be added to the case, NBC News reported.
The new indictment would be brought forth within a month, according to the prosecutor who spoke at the U.S. Federal Court in Brooklyn.
Shkreli made headlines for boosting the price of a long-established and potentially lifesaving drug by more than 5,000 percent.
"We don't believe the indictment will change anything," Benjamin Brafman, Shkreli's attorney, said outside the courthouse. Brafman also said that defense may need to explore the possibility of severing the case and splitting it into two trials.
